info@mail.ucallm.com
From Matrix Assembly to Tissue Remodeling — Empowering Comprehensive ECM Biology Research with Validated Antibody Solutions
The extracellular matrix (ECM) is a highly dynamic and biologically active network that provides structural organization, regulates cell–matrix communication, and coordinates tissue homeostasis, regeneration, and disease progression. Beyond its traditional role as a structural scaffold, the ECM functions as a critical signaling platform that controls cellular adhesion, migration, differentiation, mechanotransduction, immune regulation, and tissue-specific cellular responses.
ECM composition and architecture are continuously regulated through coordinated processes involving matrix deposition, collagen maturation, enzymatic remodeling, crosslinking regulation, and matricellular signaling pathways. These mechanisms are controlled by structural ECM proteins, matrix-modifying enzymes, fibroblast activation programs, and growth factor signaling networks. Dysregulation of ECM remodeling can disrupt tissue integrity and contribute to diverse biological and pathological processes, including:
- Fibrotic disease progression and excessive extracellular matrix accumulation
- Tumor microenvironment remodeling and metastatic niche formation
- Cancer-associated fibroblast (CAF) activation and stromal regulation
- Inflammatory tissue remodeling and immune–ECM interactions
- Organ injury, impaired regeneration, and tissue fibrosis
- Age-associated extracellular matrix deterioration and tissue dysfunction
We provide comprehensive antibody solutions for investigating ECM remodeling biology—from extracellular matrix composition profiling and collagen organization analysis to matrix degradation mechanisms, fibrosis signaling, and tumor microenvironment characterization. Validated antibodies enable researchers to study ECM structural proteins, crosslinking regulators, remodeling enzymes, matricellular factors, and fibrosis-associated signaling pathways using Western blotting (WB), immunofluorescence (IF), immunohistochemistry (IHC), and multiplex imaging platforms.
By integrating high-quality antibody reagents with advanced spatial and molecular profiling approaches, researchers can decode complex ECM regulatory networks, identify remodeling-associated biomarkers, and accelerate discoveries in fibrosis research, cancer biology, regenerative medicine, inflammation, and tissue engineering.
ECM Deposition & Crosslinking Remodeling Biomarker Antibody Portfolio
——Comprehensive Solutions for Matrix Organization, Remodeling Dynamics, and Disease Mechanism Discovery
ECM remodeling research requires integrated analysis of structural proteins, enzymatic regulators, signaling pathways, and cellular remodeling states.
Our antibody portfolio targets key ECM regulatory networks involved in:
Research Focus | Representative Biomarkers | Research Applications |
ECM Structural Deposition | COL1A1, COL1A2, COL3A1, COL4A1, FN1 | Characterization of collagen accumulation, basement membrane remodeling, and matrix architecture |
ECM Crosslinking & Matrix Maturation | LOX, LOXL1, LOXL2, TGM2, PLOD2 | Analysis of collagen crosslinking, matrix stiffness, and fibrotic ECM maturation |
ECM Degradation & Turnover | MMP1, MMP2, MMP9, MMP13, MMP14, TIMP1, TIMP2, TIMP3, TIMP4 | Investigation of matrix degradation, tissue remodeling, and protease regulation |
Matricellular Regulation | SPARC, POSTN, TNC, THBS1, CYR61 (CCN1), CTGF (CCN2) | Study of ECM-cell communication, injury response, and tumor stromal remodeling |
Fibrotic Signaling Pathways | TGFB1, SMAD2, p-SMAD2 (Ser465/467), SMAD3, p-SMAD3 (Ser423/425), SMAD4, CTGF (CCN2) | Investigation of fibroblast activation and pathological ECM production |
Activated Fibroblast & Myofibroblast States | ACTA2, FAP, PDGFRB | Identification of ECM-producing cells and fibrotic remodeling populations |
Key ECM Remodeling Biomarkers
——Molecular Functions, Research Applications, and Translational Significance
Marker | Biological Function | Research Application | Translational Relevance |
COL1A1 | Major fibrillar collagen forming structural ECM networks | Fibrosis assessment, collagen deposition studies | Widely used indicator of excessive ECM accumulation |
COL3A1 | Fibrillar collagen involved in tissue repair and remodeling | Interstitial ECM remodeling analysis | Marker of fibrotic tissue remodeling |
COL4A1 | Basement membrane collagen regulating tissue architecture | Basement membrane integrity studies | Associated with vascular and organ fibrosis |
FN1 | ECM scaffold protein regulating adhesion and migration | Matrix assembly and tumor microenvironment studies | Indicator of activated remodeling states |
LOX | Catalyzes collagen and elastin crosslinking | Matrix stiffness and ECM maturation studies | Associated with fibrosis and tumor invasion |
LOXL2 | Promotes pathological collagen crosslinking | Fibrotic ECM stabilization studies | Therapeutic target in fibrosis and cancer |
MMP2/MMP9 | ECM-degrading metalloproteinases | Matrix turnover and invasion studies | Important regulators of metastasis and tissue injury |
MMP13 | Collagen-degrading enzyme | Collagen remodeling analysis | Marker of inflammatory and degenerative remodeling |
TIMP1/2/3 | Endogenous inhibitors of MMP activity | ECM balance and protease regulation studies | Reflect ECM homeostasis disruption |
SPARC | Matricellular protein regulating collagen organization | ECM assembly and cell-matrix interaction studies | Associated with fibrosis and tumor stroma |
POSTN | Periostin promotes collagen organization | Fibroblast activation studies | Biomarker of pathological remodeling |
TNC | Injury-associated matricellular protein | Inflammation and tissue repair studies | Marker of activated ECM remodeling |
TGFB1 | Master regulator of fibrosis signaling | Fibroblast activation pathway analysis | Central driver of fibrotic disease |
SMAD2/3 | Downstream mediators of TGF-β signaling | Fibrosis pathway activation studies | Key indicators of profibrotic signaling |
CTGF/CCN2 | ECM-associated growth factor regulating collagen synthesis | Fibrosis and cancer-associated stroma studies | Established fibrosis-associated biomarker |
ACTA2 | Marker of activated myofibroblasts | Myofibroblast identification | Indicator of ECM-producing cells |
FAP | Fibroblast activation-associated protease | CAF and fibrosis research | Important stromal biomarker |
Featured ECM Remodeling Research Panels
——Comprehensive Antibody Panels for Matrix Characterization and Mechanistic Discovery
The extracellular matrix (ECM) is a highly dynamic signaling platform that regulates tissue architecture, mechanical properties, cellular communication, and disease progression. Our validated antibody panels enable comprehensive investigation of ECM remodeling — from matrix deposition and crosslinking to degradation, fibrosis activation, and tissue remodeling responses.
ECM Deposition Panel—Defining Matrix Accumulation and Structural Remodeling
Key Markers
COL1A1 | COL3A1 | COL4A1 | FN1 | SPARC |
ECM Crosslinking & Matrix Stiffness Panel—Understanding Mechanical Remodeling of the ECM
Key Markers
LOX | LOXL2 | COL1A1 | POSTN |
ECM Degradation & Remodeling Panel—Monitoring Matrix Turnover Dynamics
Key Markers
MMP2 | MMP9 | MMP1 | TIMP1 | TIMP2 |
Fibrosis Signaling Panel—Decoding Profibrotic Pathway Activation
Key Markers
TGFB1 | SMAD2 | SMAD3 | CTGF/CCN2 | ACTA2 |
Why Researchers Choose Our ECM Remodeling Antibody Solutions
Validated Targets. Comprehensive Panels. Reliable ECM Research.
Our antibody portfolio supports the complete ECM research workflow—from structural characterization to disease mechanism discovery.
Research Challenge | Our Solution |
How can I evaluate ECM accumulation? | COL1A1, COL3A1, COL4A1, FN1 antibody solutions |
How can I study matrix stiffness? | LOX and LOXL2 crosslinking markers |
How can I analyze ECM degradation? | MMP and TIMP remodeling panels |
How can I identify activated fibroblasts? | ACTA2 and FAP markers |
How can I investigate fibrosis pathways? | TGF-β/SMAD/CTGF signaling antibodies |
How can I visualize ECM heterogeneity? | Multiplex IF/IHC-compatible ECM marker combinations |
How can I improve reproducibility? | Validated antibodies optimized for WB, IF, IHC, and multiplex applications |
Key References
Naba A. Mechanisms of assembly and remodelling of the extracellular matrix. Nat Rev Mol Cell Biol. 2024 Nov;25(11):865-885.
Hu Q, Zhu Y, Mei J, Liu Y, Zhou G. Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J Hematol Oncol. 2025 Jun 19;18(1):65.
Sharma S, Prathigudupu V, Cable C, Serrano LR, Nerella S, Chen A, Hassan G, Lakins J, Valenzuela CL, Tsukui T, Ramamoorthi R, Kim JJ, Willenbring H, Mattis AN, Volk RF, Zaro BW, Coon JJ, Beresis R, DeGrado WF, Weaver VM, Christenson SA, Jo H, Chen JY. Resolving fibrosis by stimulating HSC-dependent extracellular matrix degradation. Sci Transl Med. 2025 Aug 27;17(813):eads9470.
Jiang Y, Zhang H, Wang J, Liu Y, Luo T, Hua H. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022 Mar 24;15(1):34.
Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, Zhang Z, Yang S, Xiao M. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023 Mar 11;22(1):48.
Prakash J, Shaked Y. The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics. Cancer Discov. 2024 Aug 2;14(8):1375-1388.